Pharmaceuticals, Biotechnology and Life Sciences
SUNFISH Part 2 study population includes broad range of ages and disease severities, representing a real-world spectrum of people living with Type 2 or 3 SMAEvrysdi is the first and only at home SMA treatment approved by the FDA, and has proven efficac…
MARSEILLE, France, March 16, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, March 18, 2021 at 2…
Marseille, March 16, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, March 18, 2021 at 2 p.m. CE…
TORONTO, March 15, 2021 (GLOBE NEWSWIRE) — We are advised by Avicanna Inc. that journalists and other readers should disregard the news release, “Avicanna to present at the Q1 Virtual Investor Summit” issued March 11, 2021, over GlobeNewswire.
Anchiano shareholders approve all resolutions at shareholder meeting The merged company is expected to receive approximate gross proceeds from the private financing of $45.5 million, which will be used to advance the Chemomab pipeline TEL-AVIV, Israe…
– Firdapse® Q4-20 Net Revenues of $31.0 Million, FY-20 Net Revenues of $119.1 Million – GAAP Net Income of $75.0 Million for Fiscal Year 2020 – $140.3 Million in Cash and Investments and No Funded Debt – Company to Host Quarterly Conference Call at …
Daix (France), March 15, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccha…
Announced Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia Interim Analysis Results from Second Confirmatory Phase 3 Study, RALLY, Expected in Third Quarter 2021: Interim Cohort Enrolled Efficacy Data from Animal Studies of…
– Initial dose-escalation data from Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), expected in the second half of 2021 – – Dose-escalation data from Phase 1 clinical trial for lead partnered PD-1 ch…